Cargando…

Differing environmental risk factors for membranous versus proliferative lupus nephritis

Detalles Bibliográficos
Autores principales:	Dooley, MA, Parks, CG, Cooper, GS
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3467500/ http://dx.doi.org/10.1186/ar3957

Ejemplares similares

Molecular characterization of proliferative lupus nephritis
por: Parikh, Samir V, et al.
Publicado: (2014)

Contemporary estimates of the risk of end-stage renal disease in the first decade of proliferative lupus nephritis
por: Ward, MM, et al.
Publicado: (2012)

Non-histologic factors discriminating proliferative lupus nephritis from membranous lupus nephritis
por: Kwon, Oh Chan, et al.
Publicado: (2020)

Time to lupus nephritis: impact of gender and ethnicity
por: Seligman, VA, et al.
Publicado: (2001)

Cytokine profiles of lupus patients with or without nephritis
por: Rovin, BH, et al.
Publicado: (2012)

Methodological quality of studies of end-stage renal disease risks in lupus nephritis
por: Tektonidou, Maria, et al.
Publicado: (2014)

Variation in renal biopsy and medication prescribing practices among pediatric Medicaid patients with lupus nephritis prior to end-stage renal disease in the US, 2000 to 2004
por: Hiraki, LT, et al.
Publicado: (2012)

Identification of urinary metabolites that distinguish membranous lupus nephritis from proliferative lupus nephritis and focal segmental glomerulosclerosis
por: Romick-Rosendale, Lindsey E, et al.
Publicado: (2011)

Lymphoma risk in systemic lupus: effects of treatment versus disease activity
por: Clarke, AE, et al.
Publicado: (2012)

Sociodemographics and epidemiology of serious infections requiring hospitalization among adults with systemic lupus erythematosus and lupus nephritis, 2000 to 2006
por: Feldman, Candace H, et al.
Publicado: (2014)

Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointerstitial nephritis
por: Clark, Marcus R, et al.
Publicado: (2014)

A Predictive Model for Estimation Risk of Proliferative Lupus Nephritis
por: Chen, Dong-Ni, et al.
Publicado: (2018)

Renal flare as a biomarker of incident and progressive chronic kidney disease in patients with lupus nephritis
por: Parikh, S, et al.
Publicado: (2012)

Usual source of care and geographic region are largest predictors of healthcare quality for incident lupus nephritis in US Medicaid recipients
por: Yazdany, J, et al.
Publicado: (2012)

Nonlymphoma hematological malignancies in systemic lupus erythematosus
por: Lu, M, et al.
Publicado: (2012)

Rescue treatment of severe lupus myocarditis and proliferative lupus nephritis with immunoadsorption
por: Štambuk, Sandra Karanović, et al.
Publicado: (2023)

The outcome of proliferative lupus nephritis with pulse cyclophosphamide therapy
por: Annavarajula, S. K., et al.
Publicado: (2011)

The development of membranous lupus nephritis during treatment with mycophenolate mofetil for proliferative renal disease
por: Dalton, Kristen, et al.
Publicado: (2010)

Identification of stage-specific genes associated with lupus nephritis and response to remission induction in NZB/W and NZM2410 mice
por: Bethunaickan, Ramalingam, et al.
Publicado: (2014)

Lung cancer in systemic lupus erythematosus
por: Kale, M, et al.
Publicado: (2012)

In situ cognate interactions between T-follicular helper cells and B cells characterize severe tubulointerstitial inflammation in human lupus nephritis
por: Clark, MR, et al.
Publicado: (2012)

Anti-Myeloperoxidase Antibodies Associate with Future Proliferative Lupus Nephritis
por: Olson, S. W., et al.
Publicado: (2017)

Patient-Centered Outcomes Research Institute (PCORI) multisite project to develop treatment decision aids for racial/ethnic minorities with lupus nephritis
por: Yazdany, Jinoos, et al.
Publicado: (2014)

Metabolic control of systemic lupus erythematosus: convergence of genetic and environmental factors on mitochondrial dysfunction and mTOR reveal treatment targets in lupus
por: Perl, A
Publicado: (2012)

Differences and similarities of proliferative and non-proliferative forms of biopsy-proven lupus nephritis: Single centre, cross-disciplinary experience
por: Duran, Emine, et al.
Publicado: (2022)

Expression and regulation of discoidin domain receptor 1 (DDR1) – a novel receptor for collagen – in normal human renal cells and patients with lupus nephritis
por: Boumpas, DT, et al.
Publicado: (2003)

Clinicopathologic correlations of renal microthrombosis and inflammatory markers in proliferative lupus nephritis
por: Gonzalo, Elena, et al.
Publicado: (2012)

The Steroids In the Maintenance of remission of Proliferative Lupus nephritis (SIMPL) pilot trial
por: Galbraith, Lauren, et al.
Publicado: (2014)

Hydroxychloroquine in children with proliferative lupus nephritis: a randomized clinical trial
por: Gheet, Fatma Sayed, et al.
Publicado: (2023)

Long-term renal outcomes of patients with non-proliferative lupus nephritis
por: Kang, Eun-Song, et al.
Publicado: (2023)

Area-level socioeconomic status and variation in medication use among Medicaid enrollees with incident systemic lupus erythematosus, 2000 to 2004
por: Feldman, CH, et al.
Publicado: (2012)

Developing consensus treatment plans for proliferative lupus nephritis in childhood-onset systemic lupus erythematous
por: Mina, Rina, et al.
Publicado: (2012)

Protein microarray characterization of autoantibody responses in rheumatoid arthritis and systemic lupus erythematosus
por: Robinson, W, et al.
Publicado: (2002)

Cancer risk factors in systemic lupus erythematosus: multivariate regression analysis in 16,409 patients
por: Bernatsky, Sasha, et al.
Publicado: (2014)

Biopsy-verified response of severe lupus nephritis to rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to NIH-protocol cyclophosphamide
por: van Vollenhoven, RF, et al.
Publicado: (2002)

Cost-Utility Analysis of Mycophenolate Mofetil versus Azathioprine Based Regimens for Maintenance Therapy of Proliferative Lupus Nephritis
por: Nee, Robert, et al.
Publicado: (2015)

Sickle cell nephropathy with diffuse proliferative lupus nephritis: a case report
por: Kanodia, Kamal V, et al.
Publicado: (2008)

Interleukin (IL) 16: a candidate urinary biomarker for proliferative lupus nephritis
por: Häyry, Aliisa, et al.
Publicado: (2022)

Renal Tissue Expression of BAFF and BAFF Receptors Is Associated with Proliferative Lupus Nephritis
por: Marín-Rosales, Miguel, et al.
Publicado: (2022)

Targeted delivery of PGE(2 )ameliorates autoimmune nephritis
por: Kvirkvelia, Nino, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_khjd55g75udj2je84nfq7lh076